Innovent Announces the Result of IBI351 in the P-II study for the Treatment of Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC)
Shots:
- The P-II study (NCT05005234) evaluates the safety & efficacy of GFH925 in KRAS G12C-mutated advanced solid tumors patients (n=116).The study met 1EP revealing a 46.6% ORR by IRRC along with DCR of 90.5%, mDoR of 8.3mos. & median PFS of 8.3mos while the OS was not reached.
- Furthermore, P-I data on the patients (600mg; BID) demonstrated ORR of 45.8%; DCR of 89.6% while on patients with at least 2 lines of prior treatment, ORR & DCR was 63% & 88.9% respectively. These data will be Presented at ESMO
- IBI351 is a new, orally effective KRAS G12C inhibitor designed to target the GTP/GDP exchange, a crucial step in pathway activation. It achieves this by covalently and irreversibly modifying the cysteine residue of the KRAS G12C protein
Ref: PR Newswire | Image: Innovent
Related News:- Innovent Reports NMPA Approval to the NDA for IBI351 & Grants Priority Review Designation
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
